218 related articles for article (PubMed ID: 22292446)
21. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation.
Klein S; Burke LE; Bray GA; Blair S; Allison DB; Pi-Sunyer X; Hong Y; Eckel RH;
Circulation; 2004 Nov; 110(18):2952-67. PubMed ID: 15509809
[TBL] [Abstract][Full Text] [Related]
22. What is the prognosis for new centrally-acting anti-obesity drugs?
Heal DJ; Gosden J; Smith SL
Neuropharmacology; 2012 Jul; 63(1):132-46. PubMed ID: 22313529
[TBL] [Abstract][Full Text] [Related]
23. The safety and efficacy of lorcaserin in the management of obesity.
Hess R; Cross LB
Postgrad Med; 2013 Nov; 125(6):62-72. PubMed ID: 24200762
[TBL] [Abstract][Full Text] [Related]
24. Targets for medical therapy in obesity.
Baretić M
Dig Dis; 2012; 30(2):168-72. PubMed ID: 22722433
[TBL] [Abstract][Full Text] [Related]
25. Reducing the risk of obesity: defining the role of weight loss drugs.
Ling H; Lenz TL; Burns TL; Hilleman DE
Pharmacotherapy; 2013 Dec; 33(12):1308-21. PubMed ID: 23712541
[TBL] [Abstract][Full Text] [Related]
26. Treatment of overweight and obesity: lifestyle, pharmacologic, and surgical options.
Cannon CP; Kumar A
Clin Cornerstone; 2009; 9(4):55-68; discussion 69-71. PubMed ID: 19789064
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological management of obesity in pediatric patients.
Boland CL; Harris JB; Harris KB
Ann Pharmacother; 2015 Feb; 49(2):220-32. PubMed ID: 25366340
[TBL] [Abstract][Full Text] [Related]
28. [Current status of medical therapy for obesity and the potential of novel anti-obesity drug development].
Nakazato M
Nihon Rinsho; 2013 Feb; 71(2):324-8. PubMed ID: 23631215
[TBL] [Abstract][Full Text] [Related]
29. Pharmacotherapy for weight loss: the cardiovascular effects of the old and new agents.
Walter CP; Bleske BE; Dorsch MP
J Clin Pharm Ther; 2014 Oct; 39(5):475-84. PubMed ID: 24924286
[TBL] [Abstract][Full Text] [Related]
30. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
Verpeut JL; Bello NT
Expert Opin Drug Saf; 2014 Jun; 13(6):831-41. PubMed ID: 24766397
[TBL] [Abstract][Full Text] [Related]
31. Impact of weight-loss medications on the cardiovascular system: focus on current and future anti-obesity drugs.
Drolet B; Simard C; Poirier P
Am J Cardiovasc Drugs; 2007; 7(4):273-88. PubMed ID: 17696568
[TBL] [Abstract][Full Text] [Related]
32. Interface between pharmacotherapy and genes in human obesity.
O'Connor A; Swick AG
Hum Hered; 2013; 75(2-4):116-26. PubMed ID: 24081227
[TBL] [Abstract][Full Text] [Related]
33. Pharmacotherapy of obesity: currently marketed and upcoming agents.
Bays H; Dujovne C
Am J Cardiovasc Drugs; 2002; 2(4):245-53. PubMed ID: 14727970
[TBL] [Abstract][Full Text] [Related]
34. Epidemiology of Obesity and Pharmacologic Treatment Options.
Shettar V; Patel S; Kidambi S
Nutr Clin Pract; 2017 Aug; 32(4):441-462. PubMed ID: 28632997
[TBL] [Abstract][Full Text] [Related]
35. Latest approaches for the treatment of obesity.
Jackson VM; Breen DM; Fortin JP; Liou A; Kuzmiski JB; Loomis AK; Rives ML; Shah B; Carpino PA
Expert Opin Drug Discov; 2015; 10(8):825-39. PubMed ID: 25967138
[TBL] [Abstract][Full Text] [Related]
36. Next generation of weight management medications: implications for diabetes and CVD risk.
Wharton S; Serodio KJ
Curr Cardiol Rep; 2015 May; 17(5):35. PubMed ID: 25894803
[TBL] [Abstract][Full Text] [Related]
37. New medications for treatment of obesity: metabolic and cardiovascular effects.
Pucci A; Finer N
Can J Cardiol; 2015 Feb; 31(2):142-52. PubMed ID: 25661549
[TBL] [Abstract][Full Text] [Related]
38. The impact of obesity on the pharmacology of medications used for cardiovascular risk factor control.
Sankaralingam S; Kim RB; Padwal RS
Can J Cardiol; 2015 Feb; 31(2):167-76. PubMed ID: 25661551
[TBL] [Abstract][Full Text] [Related]
39. Cardiovascular effects of current and future anti-obesity drugs.
Comerma-Steffensen S; Grann M; Andersen CU; Rungby J; Simonsen U
Curr Vasc Pharmacol; 2014 May; 12(3):493-504. PubMed ID: 24846238
[TBL] [Abstract][Full Text] [Related]
40. Investigational drugs in Phase II clinical trials for the treatment of obesity: implications for future development of novel therapies.
Jackson VM; Price DA; Carpino PA
Expert Opin Investig Drugs; 2014 Aug; 23(8):1055-66. PubMed ID: 25000213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
